Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0ER2C
|
||||
| Former ID |
DIB010821
|
||||
| Drug Name |
Triptoreline
|
||||
| Synonyms |
Triptoreline (microsphere depot formulation, prostate cancer); Triptoreline (microsphere depot formulation, prostate cancer), GP Pharm; Triptoreline (one-month sustained release formulation, prostate cancer), GP Pharm; Triptoreline (three-month sustained release formulation, prostate cancer), GP Pharm
|
||||
| Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 4 | [1] | ||
| Company |
GP Pharm SA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C64H82N18O13
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gonadotropin-releasing hormone receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| GnRH signaling pathway | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Hormone ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00633347) Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation. U.S. National Institutes of Health. | ||||
| REF 2 | Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.